FdaApplication
ANDA 206084
Identifiers
- fda_app_no: ANDA206084
Properties
| Property | Value |
|---|---|
| applicant_name | PHARMOBEDIENT CONSULTING LLC |
| application_type | ANDA |
| approval_date | 2017-04-26 |
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| LYPQOZET | ATORVASTATIN CALCIUM; EZETIMIBE | EQ 10MG BASE;10MG | TABLET;ORAL |
| LYPQOZET | ATORVASTATIN CALCIUM; EZETIMIBE | EQ 80MG BASE;10MG | TABLET;ORAL |
| LYPQOZET | ATORVASTATIN CALCIUM; EZETIMIBE | EQ 20MG BASE;10MG | TABLET;ORAL |
| LYPQOZET | ATORVASTATIN CALCIUM; EZETIMIBE | EQ 40MG BASE;10MG | TABLET;ORAL |
4 products